Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment (Q40427878)

20 September 2017

Butyrylcholinesterase: impact on symptoms and progression of cognitive impairment (English)

1 reference

20 September 2017

cognitive dysfunction

1 reference

3

1 reference

20 September 2017

Andrea Tasker

1

1 reference

PubMed ID

15853480

20 September 2017

Elaine K Perry

series ordinal

2

1 reference

20 September 2017

1 January 2005

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

20 September 2017

1 reference

20 September 2017

5

1 reference

20 September 2017

1

1 reference

20 September 2017

101-106

1 reference

A 2-year follow-up of behavioural and psychological symptoms in Alzheimer's disease.

20 September 2017

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Mild cognitive impairment in older people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Prevention of Alzheimer's disease: where we stand

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Selective loss of central cholinergic neurons in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

The cholinergic hypothesis of geriatric memory dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Ageing: the cholinergic hypothesis of cognitive decline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

The cholinergic system in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Choline and cholinergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Intravenous nicotine in Alzheimer's disease: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Regulation of attention and response to therapy in dementia by butyrylcholinesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Patterns of clinically detectable treatment effects with galantamine: a qualitative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Practice parameter: Management of dementia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Neurological cholinesterases in the normal brain and in Alzheimer's disease: relationship to plaques, tangles, and patterns of selective vulnerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Distribution of butyrylcholinesterase in the human amygdala and hippocampal formation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Widely spread butyrylcholinesterase can hydrolyze acetylcholine in the normal and Alzheimer brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Differential distribution of butyrylcholinesterase and acetylcholinesterase in the human thalamus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Neurotransmitter-related enzymes in senile dementia of the alzheimer type

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development--a study of molecular forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Changes in brain cholinesterases in senile dementia of Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

A brain regional analysis of morphologic and cholinergic abnormalities in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Cholinergic deficit in Alzheimer's disease: A study based on CSF and autopsy data

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Cholinesterases within neurofibrillary tangles related to age and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Cholinesterases and the Pathology of Alzheimer Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Butyrylcholinesterase in the life cycle of amyloid plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Glial-derived proteins activate cultured astrocytes and enhance beta amyloid-induced glial activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Acetylcholinesterase promotes beta-amyloid plaques in cerebral cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Cholinergic activity and amyloid precursor protein processing in aging and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

3-(4-[[Benzyl(methyl)amino]methyl]phenyl)-6,7-dimethoxy-2H-2-chromenone (AP2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation: a dual function lead for Alzheimer's disease therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Cholinergic function and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Phenotypic and molecular biological analysis of human butyrylcholinesterase variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Identification of the structural mutation responsible for the dibucaine-resistant (atypical) variant form of human serum cholinesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Age-dependent association between butyrylcholinesterase K-variant and Alzheimer disease-related neuropathology in human brains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

No association between the K variant of the butyrylcholinesterase gene and pathologically confirmed Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

The butyrylcholinesterase gene is neither independently nor synergistically associated with late-onset AD in clinic- and community-based populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Immunohistochemical study of distribution of apolipoproteins E and D in human cerebral beta amyloid deposits.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Methyl analogues of the experimental Alzheimer drug phenserine: synthesis and structure/activity relationships for acetyl- and butyrylcholinesterase inhibitory action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Synthesis of novel phenserine-based-selective inhibitors of butyrylcholinesterase for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.1.101

21 January 2018

Identifiers

DOI

10.1586/14737175.5.1.101

1 reference

20 September 2017

1 reference

PubMed ID

15853480